Published in ACS Chem Biol on January 04, 2013
Topoisomerases facilitate transcription of long genes linked to autism. Nature (2013) 1.93
Rad51-mediated replication fork reversal is a global response to genotoxic treatments in human cells. J Cell Biol (2015) 1.65
SLFN11 Is a Transcriptional Target of EWS-FLI1 and a Determinant of Drug Response in Ewing Sarcoma. Clin Cancer Res (2015) 1.52
Inhibitory Effect of the Noncamptothecin Topoisomerase I Inhibitor LMP-400 on Female Mice Models and Human Pheochromocytoma Cells. Endocrinology (2015) 1.42
DNA double-strand break repair pathway choice and cancer. DNA Repair (Amst) (2014) 1.33
Exploiting replicative stress to treat cancer. Nat Rev Drug Discov (2015) 1.27
Rationale for poly(ADP-ribose) polymerase (PARP) inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition. J Pharmacol Exp Ther (2014) 1.19
Tyrosyl-DNA-phosphodiesterases (TDP1 and TDP2). DNA Repair (Amst) (2014) 1.17
Topoisomerase-mediated chromosomal break repair: an emerging player in many games. Nat Rev Cancer (2015) 1.15
PARP1-TDP1 coupling for the repair of topoisomerase I-induced DNA damage. Nucleic Acids Res (2014) 1.11
Involvement of the host DNA-repair enzyme TDP2 in formation of the covalently closed circular DNA persistence reservoir of hepatitis B viruses. Proc Natl Acad Sci U S A (2014) 1.11
Differential and common DNA repair pathways for topoisomerase I- and II-targeted drugs in a genetic DT40 repair cell screen panel. Mol Cancer Ther (2013) 1.09
Roles of eukaryotic topoisomerases in transcription, replication and genomic stability. Nat Rev Mol Cell Biol (2016) 1.05
Topoisomerase II and leukemia. Ann N Y Acad Sci (2014) 1.04
The cutting edges in DNA repair, licensing, and fidelity: DNA and RNA repair nucleases sculpt DNA to measure twice, cut once. DNA Repair (Amst) (2014) 1.04
Recognition and repair of chemically heterogeneous structures at DNA ends. Environ Mol Mutagen (2014) 1.00
Genome-wide transcriptional effects of the anti-cancer agent camptothecin. PLoS One (2013) 1.00
Mitochondrial topoisomerase I (top1mt) is a novel limiting factor of doxorubicin cardiotoxicity. Clin Cancer Res (2014) 0.98
Current concepts in clinical radiation oncology. Radiat Environ Biophys (2013) 0.97
The nuclear γ-H2AX apoptotic ring: implications for cancers and autoimmune diseases. Cell Mol Life Sci (2014) 0.93
PARP3 affects the relative contribution of homologous recombination and nonhomologous end-joining pathways. Nucleic Acids Res (2014) 0.93
Proteolytic degradation of topoisomerase II (Top2) enables the processing of Top2·DNA and Top2·RNA covalent complexes by tyrosyl-DNA-phosphodiesterase 2 (TDP2). J Biol Chem (2014) 0.91
Phytochemicals as Anticancer and Chemopreventive Topoisomerase II Poisons. Phytochem Rev (2014) 0.91
DNA break mapping reveals topoisomerase II activity genome-wide. Int J Mol Sci (2014) 0.91
ATR inhibitors VE-821 and VX-970 sensitize cancer cells to topoisomerase i inhibitors by disabling DNA replication initiation and fork elongation responses. Cancer Res (2014) 0.89
Tetrameric Ctp1 coordinates DNA binding and DNA bridging in DNA double-strand-break repair. Nat Struct Mol Biol (2015) 0.89
Inhibition of Topoisomerase (DNA) I (TOP1): DNA Damage Repair and Anticancer Therapy. Biomolecules (2015) 0.89
Topoisomerase 1 inhibition reversibly impairs synaptic function. Proc Natl Acad Sci U S A (2014) 0.86
The dual-acting chemotherapeutic agent Alchemix induces cell death independently of ATM and p53. Oncogene (2014) 0.85
DNA torsion as a feedback mediator of transcription and chromatin dynamics. Nucleus (2014) 0.85
Structural basis of DNA gyrase inhibition by antibacterial QPT-1, anticancer drug etoposide and moxifloxacin. Nat Commun (2015) 0.84
Epigenetic and genetic inactivation of tyrosyl-DNA-phosphodiesterase 1 (TDP1) in human lung cancer cells from the NCI-60 panel. DNA Repair (Amst) (2013) 0.84
Gold(III) macrocycles: nucleotide-specific unconventional catalytic inhibitors of human topoisomerase I. J Am Chem Soc (2014) 0.83
Recombination and replication. Cold Spring Harb Perspect Biol (2014) 0.83
Synthesis and antibacterial evaluation of anziaic acid and analogues as topoisomerase I inhibitors. Medchemcomm (2013) 0.83
Replication-dependent and transcription-dependent mechanisms of DNA double-strand break induction by the topoisomerase 2-targeting drug etoposide. PLoS One (2013) 0.83
Lack of mitochondrial topoisomerase I (TOP1mt) impairs liver regeneration. Proc Natl Acad Sci U S A (2015) 0.82
Effects of Olive Metabolites on DNA Cleavage Mediated by Human Type II Topoisomerases. Biochemistry (2015) 0.82
Polynucleotide 3'-terminal phosphate modifications by RNA and DNA ligases. J Biol Chem (2014) 0.82
Poisoning of mitochondrial topoisomerase I by lamellarin D. Mol Pharmacol (2014) 0.82
Strategic role of the ubiquitin-dependent segregase p97 (VCP or Cdc48) in DNA replication. Chromosoma (2016) 0.81
Oxidative Transformation of Demethoxy- and Bisdemethoxycurcumin: Products, Mechanism of Formation, and Poisoning of Human Topoisomerase IIα. Chem Res Toxicol (2015) 0.81
Catalytic core of human topoisomerase IIα: insights into enzyme-DNA interactions and drug mechanism. Biochemistry (2014) 0.81
Structural basis for DNA cleavage by the potent antiproliferative agent (-)-lomaiviticin A. Proc Natl Acad Sci U S A (2016) 0.81
The Dynamic Interplay Between DNA Topoisomerases and DNA Topology. Biophys Rev (2016) 0.81
Approaches to identifying synthetic lethal interactions in cancer. Yale J Biol Med (2015) 0.81
New treatment option for ovarian cancer: PARP inhibitors. Gynecol Oncol Res Pract (2016) 0.80
Novel DNA topoisomerase IIα inhibitors from combined ligand- and structure-based virtual screening. PLoS One (2014) 0.80
Etoposide quinone is a covalent poison of human topoisomerase IIβ. Biochemistry (2014) 0.80
Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors. Clin Cancer Res (2016) 0.79
Targeting Mycobacterium tuberculosis topoisomerase I by small-molecule inhibitors. Antimicrob Agents Chemother (2014) 0.79
Ribonucleotide triggered DNA damage and RNA-DNA damage responses. RNA Biol (2014) 0.79
Insights from the Structure of Mycobacterium tuberculosis Topoisomerase I with a Novel Protein Fold. J Mol Biol (2015) 0.79
Targeting bacterial topoisomerase I to meet the challenge of finding new antibiotics. Future Med Chem (2015) 0.79
Molecular characterization of irinotecan (SN-38) resistant human breast cancer cell lines. BMC Cancer (2016) 0.79
The applications of the novel polymeric fluoropyrimidine F10 in cancer treatment: current evidence. Future Oncol (2016) 0.79
Abacavir, an anti-HIV-1 drug, targets TDP1-deficient adult T cell leukemia. Sci Adv (2015) 0.78
Identification of genes that are essential to restrict genome duplication to once per cell division. Oncotarget (2016) 0.78
Synthesis and biological evaluation of 6-substituted indolizinoquinolinediones as catalytic DNA topoisomerase I inhibitors. Eur J Med Chem (2015) 0.78
DNA double-strand breaks with 5' adducts are efficiently channeled to the DNA2-mediated resection pathway. Nucleic Acids Res (2015) 0.78
Genome-destabilizing effects associated with top1 loss or accumulation of top1 cleavage complexes in yeast. PLoS Genet (2015) 0.78
Modification of topoisomerases in mammospheres derived from breast cancer cell line: clinical implications for combined treatments with tyrosine kinase inhibitors. BMC Cancer (2014) 0.78
Structure-based design, synthesis and biological testing of etoposide analog epipodophyllotoxin-N-mustard hybrid compounds designed to covalently bind to topoisomerase II and DNA. Bioorg Med Chem (2014) 0.78
Allyl isothiocyanate induces replication-associated DNA damage response in NSCLC cells and sensitizes to ionizing radiation. Oncotarget (2015) 0.78
ERK3 regulates TDP2-mediated DNA damage response and chemoresistance in lung cancer cells. Oncotarget (2016) 0.78
Molecular and Pharmacologic Properties of the Anticancer Quinolone Derivative Vosaroxin: A New Therapeutic Agent for Acute Myeloid Leukemia. Drugs (2016) 0.78
Reversal of DNA damage induced Topoisomerase 2 DNA-protein crosslinks by Tdp2. Nucleic Acids Res (2016) 0.77
Tipin functions in the protection against topoisomerase I inhibitor. J Biol Chem (2014) 0.77
Metronomic topotecan impedes tumor growth of MYCN-amplified neuroblastoma cells in vitro and in vivo by therapy induced senescence. Oncotarget (2016) 0.77
Enzyme mechanism-based, oxidative DNA-protein cross-links formed with DNA polymerase β in vivo. Proc Natl Acad Sci U S A (2015) 0.77
Synthesis and evaluation of (18)F-labeled ATP competitive inhibitors of topoisomerase II as probes for imaging topoisomerase II expression. Eur J Med Chem (2014) 0.77
Biochemical assays for the discovery of TDP1 inhibitors. Mol Cancer Ther (2014) 0.77
Copper-mediated genotoxic stress is attenuated by the overexpression of the DNA repair gene MtTdp2α (tyrosyl-DNA phosphodiesterase 2) in Medicago truncatula plants. Plant Cell Rep (2014) 0.77
Structure-based design, synthesis and biological testing of piperazine-linked bis-epipodophyllotoxin etoposide analogs. Bioorg Med Chem (2015) 0.77
PLK1 is a critical determinant of tumor cell sensitivity to CPT11 and its inhibition enhances the drug antitumor efficacy in squamous cell carcinoma models sensitive and resistant to camptothecins. Oncotarget (2015) 0.77
Rad18 is required for functional interactions between FANCD2, BRCA2, and Rad51 to repair DNA topoisomerase 1-poisons induced lesions and promote fork recovery. Oncotarget (2016) 0.77
Targeting the gyrase of Plasmodium falciparum with topoisomerase poisons. Biochem Pharmacol (2015) 0.77
G-quadruplex DNA and ligand interaction in living cells using NMR spectroscopy. Chem Sci (2015) 0.77
DDK dependent regulation of TOP2A at centromeres revealed by a chemical genetics approach. Nucleic Acids Res (2016) 0.76
G9a inhibition potentiates the anti-tumour activity of DNA double-strand break inducing agents by impairing DNA repair independent of p53 status. Cancer Lett (2016) 0.76
Differential cytotoxicity induced by the Titanium(IV)Salan complex Tc52 in G2-phase independent of DNA damage. BMC Cancer (2016) 0.76
Synthesis of a peptide-universal nucleotide antigen: towards next-generation antibodies to detect topoisomerase I-DNA covalent complexes. Org Biomol Chem (2016) 0.76
A high through-put screen for small molecules modulating MCM2 phosphorylation identifies Ryuvidine as an inducer of the DNA damage response. PLoS One (2014) 0.76
Structure of a quinolone-stabilized cleavage complex of topoisomerase IV from Klebsiella pneumoniae and comparison with a related Streptococcus pneumoniae complex. Acta Crystallogr D Struct Biol (2016) 0.76
CFS-1686 causes cell cycle arrest at intra-S phase by interference of interaction of topoisomerase 1 with DNA. PLoS One (2014) 0.76
Deoxynybomycins inhibit mutant DNA gyrase and rescue mice infected with fluoroquinolone-resistant bacteria. Nat Commun (2015) 0.76
Poly(ADP-ribose) polymers regulate DNA topoisomerase I (Top1) nuclear dynamics and camptothecin sensitivity in living cells. Nucleic Acids Res (2016) 0.76
Toward the development of a novel non-RGD cyclic peptide drug conjugate for treatment of human metastatic melanoma. Oncotarget (2016) 0.75
Targeting DNA Replication Stress for Cancer Therapy. Genes (Basel) (2016) 0.75
RNF168 and USP10 regulate topoisomerase IIα function via opposing effects on its ubiquitylation. Nat Commun (2016) 0.75
A Novel Spirooxindole Derivative Inhibits the Growth of Leishmania donovani Parasites both In Vitro and In Vivo by Targeting Type IB Topoisomerase. Antimicrob Agents Chemother (2016) 0.75
Pharmacodynamic endpoints as clinical trial objectives to answer important questions in oncology drug development. Semin Oncol (2016) 0.75
Synthesis, evaluation, and CoMFA study of fluoroquinophenoxazine derivatives as bacterial topoisomerase IA inhibitors. Eur J Med Chem (2016) 0.75
Identification of novel PARP inhibitors using a cell-based TDP1 inhibitory assay in a quantitative high-throughput screening platform. DNA Repair (Amst) (2014) 0.75
Suppression of lupus nephritis and skin lesions in MRL/lpr mice by administration of the topoisomerase I inhibitor irinotecan. Arthritis Res Ther (2016) 0.75
Exploring the active site of the Streptococcus pneumoniae topoisomerase IV-DNA cleavage complex with novel 7,8-bridged fluoroquinolones. Open Biol (2016) 0.75
A simplified protocol for high-yield expression and purification of bacterial topoisomerase I. Protein Expr Purif (2016) 0.75
Inhibition of Zn(II) binding type IA topoisomerases by organomercury compounds and Hg(II). PLoS One (2015) 0.75
Tyrosyl-DNA Phosphodiesterase I a critical survival factor for neuronal development and homeostasis. J Neurol Neuromedicine (2016) 0.75
Dual Inhibitors Against Topoisomerases and Histone Deacetylases. J Cancer Prev (2015) 0.75
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature (2012) 31.78
DNA gyrase: an enzyme that introduces superhelical turns into DNA. Proc Natl Acad Sci U S A (1976) 17.42
Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature (2012) 15.91
1,8-NAPHTHYRIDINE DERIVATIVES. A NEW CLASS OF CHEMOTHERAPEUTIC AGENTS. J Med Pharm Chem (1962) 13.97
DNA topoisomerases. Annu Rev Biochem (1981) 13.42
DNA topoisomerases: structure, function, and mechanism. Annu Rev Biochem (2001) 12.53
DNA topoisomerases. Annu Rev Biochem (1996) 9.48
The Bloom's syndrome helicase suppresses crossing over during homologous recombination. Nature (2003) 8.68
Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem (1985) 8.60
A topoisomerase IIbeta-mediated dsDNA break required for regulated transcription. Science (2006) 6.71
DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem Biol (2010) 5.61
Targeting DNA topoisomerase II in cancer chemotherapy. Nat Rev Cancer (2009) 5.06
Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science (1984) 4.52
Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy. J Natl Cancer Inst (2009) 4.24
A model for the mechanism of human topoisomerase I. Science (1998) 4.10
Nonintercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. J Biol Chem (1984) 3.98
Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements. Nat Genet (2010) 3.83
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. Cancer Res (2012) 3.74
The mechanism of topoisomerase I poisoning by a camptothecin analog. Proc Natl Acad Sci U S A (2002) 3.71
Type IIA topoisomerase inhibition by a new class of antibacterial agents. Nature (2010) 3.58
DNA topoisomerases: harnessing and constraining energy to govern chromosome topology. Q Rev Biophys (2008) 3.50
Yeast gene for a Tyr-DNA phosphodiesterase that repairs topoisomerase I complexes. Science (1999) 3.29
Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med (2012) 3.20
DNA topoisomerase-targeting antitumor drugs can be studied in yeast. Proc Natl Acad Sci U S A (1988) 3.10
DNA topoisomerase II and its growing repertoire of biological functions. Nat Rev Cancer (2009) 3.05
A eukaryotic enzyme that can disjoin dead-end covalent complexes between DNA and type I topoisomerases. Proc Natl Acad Sci U S A (1996) 2.96
Antibody-drug conjugates for cancer: poised to deliver? Nat Rev Drug Discov (2010) 2.96
Friction and torque govern the relaxation of DNA supercoils by eukaryotic topoisomerase IB. Nature (2005) 2.91
Mutation of TDP1, encoding a topoisomerase I-dependent DNA damage repair enzyme, in spinocerebellar ataxia with axonal neuropathy. Nat Genet (2002) 2.91
Antitumour drugs impede DNA uncoiling by topoisomerase I. Nature (2007) 2.77
Bacterial topoisomerase inhibitors: quinolone and pyridone antibacterial agents. Chem Rev (2005) 2.70
DNA topoisomerase I inhibitors: chemistry, biology, and interfacial inhibition. Chem Rev (2009) 2.65
The DNA cleavage reaction of topoisomerase II: wolf in sheep's clothing. Nucleic Acids Res (2008) 2.64
CellMiner: a web-based suite of genomic and pharmacologic tools to explore transcript and drug patterns in the NCI-60 cell line set. Cancer Res (2012) 2.57
Topoisomerase levels determine chemotherapy response in vitro and in vivo. Proc Natl Acad Sci U S A (2008) 2.53
Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML. Cell (2012) 2.51
Yeast Tdp1 and Rad1-Rad10 function as redundant pathways for repairing Top1 replicative damage. Proc Natl Acad Sci U S A (2002) 2.50
Mechanism of action of eukaryotic topoisomerase II and drugs targeted to the enzyme. Biochim Biophys Acta (1998) 2.35
A human 5'-tyrosyl DNA phosphodiesterase that repairs topoisomerase-mediated DNA damage. Nature (2009) 2.33
Novel indenoisoquinolines NSC 725776 and NSC 724998 produce persistent topoisomerase I cleavage complexes and overcome multidrug resistance. Cancer Res (2007) 2.26
The tyrosyl-DNA phosphodiesterase Tdp1 is a member of the phospholipase D superfamily. Proc Natl Acad Sci U S A (2001) 2.18
Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition. Cancer Res (2001) 2.18
Repair of topoisomerase I-mediated DNA damage. Prog Nucleic Acid Res Mol Biol (2006) 2.16
Topoisomerase II as a target for anticancer drugs: when enzymes stop being nice. Prog Nucleic Acid Res Mol Biol (2000) 2.13
Structures of three classes of anticancer agents bound to the human topoisomerase I-DNA covalent complex. J Med Chem (2005) 2.12
DNA topoisomerase I--targeted chemotherapy of human colon cancer in xenografts. Science (1989) 2.11
Structural insight into the quinolone-DNA cleavage complex of type IIA topoisomerases. Nat Struct Mol Biol (2009) 2.05
Evidence that DNA topoisomerase I is necessary for the cytotoxic effects of camptothecin. Mol Pharmacol (1988) 1.95
Origin and evolution of DNA topoisomerases. Biochimie (2007) 1.94
Pathways for repair of topoisomerase I covalent complexes in Saccharomyces cerevisiae. Genes Cells (2001) 1.93
Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies. Proc Natl Acad Sci U S A (2007) 1.92
SCAN1 mutant Tdp1 accumulates the enzyme--DNA intermediate and causes camptothecin hypersensitivity. EMBO J (2005) 1.88
Intercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. J Biol Chem (1984) 1.88
Structural basis of type II topoisomerase inhibition by the anticancer drug etoposide. Science (2011) 1.83
Interfacial inhibitors: targeting macromolecular complexes. Nat Rev Drug Discov (2011) 1.80
Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials. J Natl Cancer Inst (1994) 1.79
Poly(ADP-ribose) polymerase and XPF-ERCC1 participate in distinct pathways for the repair of topoisomerase I-induced DNA damage in mammalian cells. Nucleic Acids Res (2011) 1.76
Effect of local DNA sequence on topoisomerase I cleavage in the presence or absence of camptothecin. J Biol Chem (1991) 1.74
Quinolones: action and resistance updated. Curr Top Med Chem (2009) 1.73
Preclinical modeling of a phase 0 clinical trial: qualification of a pharmacodynamic assay of poly (ADP-ribose) polymerase in tumor biopsies of mouse xenografts. Clin Cancer Res (2008) 1.70
Tyrosyl-DNA phosphodiesterase (Tdp1) participates in the repair of Top2-mediated DNA damage. Proc Natl Acad Sci U S A (2006) 1.70
Protein-linked DNA strand breaks induced by NSC 314622, a novel noncamptothecin topoisomerase I poison. Mol Pharmacol (1998) 1.69
The indenoisoquinoline noncamptothecin topoisomerase I inhibitors: update and perspectives. Mol Cancer Ther (2009) 1.64
Protein-associated deoxyribonucleic acid strand breaks in L1210 cells treated with the deoxyribonucleic acid intercalating agents 4'-(9-acridinylamino) methanesulfon-m-anisidide and adriamycin. Biochemistry (1981) 1.63
Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells. Cancer Res (1999) 1.62
DNA cleavage assay for the identification of topoisomerase I inhibitors. Nat Protoc (2008) 1.61
Global fluoroquinolone resistance epidemiology and implictions for clinical use. Interdiscip Perspect Infect Dis (2012) 1.55
Recent advances in understanding structure-function relationships in the type II topoisomerase mechanism. Biochem Soc Trans (2005) 1.55
Bacterial topoisomerase I as a target for discovery of antibacterial compounds. Nucleic Acids Res (2008) 1.55
Next generation topoisomerase I inhibitors: Rationale and biomarker strategies. Biochem Pharmacol (2007) 1.55
Topoisomerase I inhibitors: selectivity and cellular resistance. Drug Resist Updat (1999) 1.53
Nonclassic functions of human topoisomerase I: genome-wide and pharmacologic analyses. Cancer Res (2007) 1.51
The crystal structure of human tyrosyl-DNA phosphodiesterase, Tdp1. Structure (2002) 1.51
Local sequence requirements for DNA cleavage by mammalian topoisomerase II in the presence of doxorubicin. Nucleic Acids Res (1990) 1.50
Crystal structure of a transition state mimic for Tdp1 assembled from vanadate, DNA, and a topoisomerase I-derived peptide. Chem Biol (2003) 1.47
Structural basis of gate-DNA breakage and resealing by type II topoisomerases. PLoS One (2010) 1.45
Protein-linked DNA strand breaks induced in mammalian cells by camptothecin, an inhibitor of topoisomerase I. Cancer Res (1989) 1.43
Interfacial inhibition of macromolecular interactions: nature's paradigm for drug discovery. Trends Pharmacol Sci (2005) 1.43
Tyrosyl-DNA phosphodiesterase as a target for anticancer therapy. Anticancer Agents Med Chem (2008) 1.43
Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro. Br J Cancer (2001) 1.42
A protease pathway for the repair of topoisomerase II-DNA covalent complexes. J Biol Chem (2006) 1.41
Topoisomerase II and the etiology of chromosomal translocations. DNA Repair (Amst) (2006) 1.41
DNA gyrase as a drug target. Biochem Soc Trans (1999) 1.40
Structure of a complex between E. coli DNA topoisomerase I and single-stranded DNA. Structure (2003) 1.39
Mechanisms of resistance to topoisomerase I-targeting drugs. Oncogene (2003) 1.39
Insights into substrate binding and catalytic mechanism of human tyrosyl-DNA phosphodiesterase (Tdp1) from vanadate and tungstate-inhibited structures. J Mol Biol (2002) 1.37
Topoisomerase I levels in the NCI-60 cancer cell line panel determined by validated ELISA and microarray analysis and correlation with indenoisoquinoline sensitivity. Mol Cancer Ther (2009) 1.37
Processing of nucleopeptides mimicking the topoisomerase I-DNA covalent complex by tyrosyl-DNA phosphodiesterase. Nucleic Acids Res (2002) 1.37
A novel norindenoisoquinoline structure reveals a common interfacial inhibitor paradigm for ternary trapping of the topoisomerase I-DNA covalent complex. Mol Cancer Ther (2006) 1.36
Mus81-mediated DNA cleavage resolves replication forks stalled by topoisomerase I-DNA complexes. J Cell Biol (2011) 1.36
Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents. Proc Natl Acad Sci U S A (2012) 1.35
Development of a validated immunofluorescence assay for γH2AX as a pharmacodynamic marker of topoisomerase I inhibitor activity. Clin Cancer Res (2010) 1.35
A ubiquitin-proteasome pathway for the repair of topoisomerase I-DNA covalent complexes. J Biol Chem (2008) 1.31
Model for MLL translocations in therapy-related leukemia involving topoisomerase IIβ-mediated DNA strand breaks and gene proximity. Proc Natl Acad Sci U S A (2012) 1.29
Voreloxin is an anticancer quinolone derivative that intercalates DNA and poisons topoisomerase II. PLoS One (2010) 1.29
Single- and double-strand DNA breakage and repair in human lung adenocarcinoma cells exposed to etoposide and teniposide. Cancer Res (1985) 1.28
Camptothecin and taxol: discovery to clinic--thirteenth Bruce F. Cain Memorial Award Lecture. Cancer Res (1995) 1.27
Analysis of topoisomerase I/DNA complexes in patients administered topotecan. Cancer Res (1995) 1.27
Tyrosyl-DNA phosphodiesterase 1 (TDP1) repairs DNA damage induced by topoisomerases I and II and base alkylation in vertebrate cells. J Biol Chem (2012) 1.26